Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 627-637

  Di Paolo, Antonello ^a,b,c,d   Danesi, Romano ^a,b,c,d   Vannozzi, Francesca ^a,b,c,d   Falcone, Alfredo ^a,b,c,d   Mini, Enrico ^a,b,c,d   Cionini, Luca ^a,b,c,d   Ibrahim, Toni ^a,b,c,d   Amadori, Dino ^a,b,c,d   Del Tacca, Mario ^a,b,c,d  

^a UNIVERSITY OF PISA   (Italy)

^b Civil Hospital   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CLINICAL ARTICLE; COLORECTAL CANCER; CONJUNCTIVITIS; CYSTITIS; DERMATITIS; DIARRHEA; DRUG MONITORING; ENZYME ACTIVITY; EPIGASTRIC PAIN; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RHINITIS; STOMATITIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS;

EID: 0036913715     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.128867     Document Type: Article

References (21)

1. Allegra CJ, Grem JL. Antimetabolites. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997. p. 432-52.
2. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627-30.
3. Bocci G, Danesi R, Di Paolo A, Innocenti F, Allegrini G, Falcone A, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000;6:3032-7.
4. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001;12:1301-6.
5. Sorensen BT, Stromgren A, Jacobsen P, Jacobsen A. A limited sampling method for the estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993;31:324-7.
6. Huitema ADR, Mathôt RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods. Clin Pharmacol Ther 2000;67:621-30.
7. Danesi R, Fogli S, Gennari A, Conte PF, Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002;41:431-44.
8. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival. J Clin Oncol 1997;15:2432-41.
9. QUASAR Collaborative Group. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet 2000;355:1588-96.
10. Jodrell DI, Murray LS, Hawtof J, Graham MA, Egorin MJ. A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 1996; 37:356-62.
11. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 1988;44:232-8.
12. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997.
13. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
14. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients and clinical implications in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-6.
15. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996;2:507-10.
16. Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokinet 1999;36:391-8.
17. Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, et al. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1991;28:63-81.
18. Gamelin E, Boisdron-Celle M, Guérin-Meyer R, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-10.
19. Diasio RB, Harris BE. Clinical pharmacokinetics of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
20. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002;8:768-74.
21. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NON-MEM analysis. Eur J Cancer 1998;34:92-7.